DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FARXIGA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

All Clinical Trials for Farxiga

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02371187	Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?	Recruiting	AstraZeneca	Phase 2	2015-06-01	Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
NCT02371187	Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?	Recruiting	Christopher Bell	Phase 2	2015-06-01	Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.
NCT02372955	Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes	Recruiting	Gulf Regional Research & Educational Services, LLC	Phase 4	2015-02-01	Dapagliflozin has been shown to lower clinic systolic and diastolic blood pressure in patients with type 2 diabetes mellitus. The exact mechanism(s) by which dapagliflozin lowers clinic SBP is unknown. The primary objective of the study is to determine the effect of dapagliflozin , 10 mg daily, on parameters of arterial stiffness: aPWV, augmentation index (AI), 24-hour blood pressure patterns, SBP, and pulse pressure. Urinary sodium excretion, and Intravascular volume status will be recorded. The study will involve 21 subjects for a duration of 16 weeks.
NCT02518945	Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes	Recruiting	University at Buffalo	Phase 3	2015-08-01	This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.
NCT02520518	Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?	Recruiting	AstraZeneca	Phase 2	2015-08-01	Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.
NCT02520518	Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?	Recruiting	Christopher Bell	Phase 2	2015-08-01	Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.
NCT02592421	SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2	Recruiting	The University of Texas Health Science Center at San Antonio	Phase 3	2015-10-01	In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary